Clinical Application of Circulating Tumour Cells in Prostate Cancer: From Bench to Bedside and Back.

ABSTRACT: Prostate cancer is the most common cancer in men worldwide. To improve future drug development and patient management, surrogate biomarkers associated with relevant outcomes are required. Circulating tumour cells (CTCs) are tumour cells that can enter the circulatory system, and are principally responsible for the development of metastasis at distant sites. In recent years, interest in detecting CTCs as a surrogate biomarker has ghiiukjrown. Clinical studies have revealed that high levels of CTCs in the blood correlate with disease progression in patients with prostate cancer; however, their predictive value for monitoring therapeutic response is less clear. Despite the important progress in CTC clinical development, there are critical requirements for the implementation of their analysis

SUBMITTER: Leon-Mateos L 

PROVIDER: S-EPMC5037845 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature